CymaBay Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.03.24	Gilead Sciences Completes Acquisition Of CymaBay Therapeutics (RTTNews)
11.03.24	Gilead Sciences Announces Expiration Of HSR Waiting Period For CymaBay Tender Offer (RTTNews)
12.02.24	CymaBay Announces FDA Acceptance Of NDA, Priority Review For Seladelpar; Stock Up 24% (RTTNews)
12.02.24	Gilead To Acquire CymaBay; To Enhance Revenue Growth Upon Approval Of Seladelpar (RTTNews)
03.01.24	CymaBay's New ENHANCE Data Shows Correlation Between IL-31 Reduction And Pruritis Improvement (RTTNews)
15.12.23	CymaBay Therapeutics Submits New Drug Application To FDA For Seladelpar (RTTNews)
15.12.23	CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis (PR Newswire)
13.11.23	CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting® (PR Newswire)
12.09.23	These 9 Stocks Touched New Highs (RTTNews)
11.09.23	CymaBay Launches Public Offering Of $150 Mln Of Shares, Warrants (RTTNews)
07.09.23	CymaBay Announces Positive Results From Phase 3 Study Of Seladelpar In Primary Biliary Cholangitis (RTTNews)
07.09.23	CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis (PR Newswire)
10.08.23	CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase (PR Newswire)
21.06.23	CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels (PR Newswire)
07.06.23	CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023 (PR Newswire)
09.01.23	CymaBay, Kaken To Develop And Commercialize Seladelpar In Japan For Primary Biliary Cholangitis (RTTNews)
04.08.20	ALRN To Report Data In Q4, IMUC Hits New High, VYGR Pulls Out Of ABBV Deal, VNDA To Face FDA In Dec. (RTTNews)
23.07.20	Stock Alert: CymaBay Jumps 35% After FDA Lifts All Clinical Holds On Seladelpar (RTTNews)
23.07.20	CymaBay Says Clinical Hold Lifted On Seladelpar INDs In NASH, PBC And PSC; Stock Up (RTTNews)
26.11.19	CCXI Is Red Hot, ZGNX On Watch, FDA Snubs ADMP (RTTNews)
10.11.18	Week Ahead In Pharmaceuticals: 13 Stocks To Watch (EIDX, NOVN, ZYME...) (RTTNews)
04.09.18	Is There Still Room To Run For These Biotech Stocks? (RTTNews)
26.06.18	FDA Approves 1st Cannabis-Based Drug, TECH Opens Wallet Again, MACK, SPHS Plunge (RTTNews)
12.04.18	CBAY Walks The Talk, MYND Explodes, NITE Sparkles, NVLN Awaits CHMP Opinion (RTTNews)
14.02.18	TYHT Shines, CATB Moves Ahead, ATRA Hits New High, CBAY Is Turning Heads (RTTNews)
25.10.17	ATOS Catches Eyes, PTIE Gains, CNCE Hits Right Notes, SMMT Keeps Sliding (RTTNews)
08.08.17	Breakfast Technical Briefing on Biotech Stocks -- CytRx, Aeterna Zentaris, Capricor Therapeutics, and Cymabay Therapeutics (PR Newswire)
20.07.17	CymaBay Prices Offering At $6.50/Share (RTTNews)
18.07.17	Biotech Stocks Growing Faster Than Other Sectors Fueled by Breakthroughs in R&D and Clinical Trials (PR Newswire)
18.07.17	Biotech Stocks Growing Faster Than Other Sectors Fueled by Breakthroughs in R&D and Clinical Trials (PR Newswire)
18.07.17	FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges (RTTNews)
15.06.17	Today's Research Report Coverage on Biotech Stocks -- Jaguar Animal Health, Biostage, Cymabay Therapeutics, and Catalyst Biosciences (PR Newswire)
26.04.17	How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences (PR Newswire)
17.03.17	Research Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx Pharma, Cymabay Therapeutics, and Omeros (PR Newswire)
10.03.17	Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM... (RTTNews)
28.02.17	Gainers & Losers Of Feb.27: LJPC, NVAX, KTOV, CYCC, ARGS... (RTTNews)
31.01.17	Gainers & Losers Of The Day: CALA, EVOK, EYEG, OCRX, TENX... (RTTNews)
04.01.17	AGRX Fails To SECURE Investor Confidence, ITEK Hit Hard, CBAY Rises On Kowa Deal (RTTNews)
18.03.16	TTHI, HBIO Put On Notice, Elite Gets FDA Date, VYGR Gets Ready To Sail (RTTNews)
20.01.16	CymaBay Successfully Completes End-of-Phase 2 Discussions With FDA; Stock Surges (RTTNews)
24.04.15	AERI's Rocket-1 Crashes, ACT Launches Avycaz, DRNA Extends Gain After Hours (RTTNews)
25.03.15	CymaBay: FDA Grants Orphan Drug Designation For MBX-8025 - Quick Facts (RTTNews)
25.02.15	ADMP Proves A Point, PETX Regains Drug Rights, CBAY Dips, NKTR On Watch (RTTNews)
30.09.14	SLXP Gets FDA Nod, Catalyst Makes Right Moves, TKAI On Watch, AMAG Opens Wallet (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu CymaBay Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten